Therapeutic effect and safety of ozone therapy in sars cov-2 patients. Cuban experience

Abstract

SARS-Cov2, the virus causing COVID-19, is distributed globally since December 2019, classified as a pandemic by the World Health Organization. The virus is known to cause Acute Respiratory Distress Syndrome (ARDS). Cytokine storm is considered to be one of the major causes of ARDS and multiple-organ failure. Due to the high lethality of SARS-CoV2 infections and its economic and social impact, it is necessary to seek new therapeutic procedures. It has been demonstrated that ozone therapy produces a significant improvement in blood flow and oxygenation of ischemic tissues. Also, ozone can achieve an equilibrium between Nrf2 and NF-?B factors, modulating oxidative stress and the expression of pro-inflammatory cytokines. Levels of reduced glutathione (GSH), the key antioxidant guardian in all tissues, could be critical in extinguishing the exacerbated inflammation that triggers organ failure in COVID-19. The reduced levels of GSH are clinically associated with severe disease. It is well documented that ozone activates the level of GSH. In clinical studies, ozone has a significant role in the treatment of pulmonary and vascular diseases. An exploratory, controlled, open and monocentric study was carried out in 32 patients with mild to moderate symptoms, distributed at random in two groups of 16 patients each. The first group received rectal ozone therapy (ozone concentration between 25 and 40 mg/L and volume between 100 and 200 ml, twice per day) together with conventional treatment with Kaletra Lopinavir/Ritonavir), chloroquine and/or Heberferon®, and the second group only conventional treatment. The result of the RT-PCR and the evolution of the clinical signs were the primary efficacy variables. Secondary efficacy variables were ferritin, C-reactive protein, oxidative stress biomarkers, cellular indicators of inflammation, biochemical and hematological variables, and the presence of adverse effects. Patients (81%) who received rectal ozone therapy had a negative RT-PCR after the tenth ozone therapy application (after 5 days), with significant differences from the control group at the same time. In all patients, improvements in the levels of C-reactive protein and cellular indicators of inflammation were achieved at the end of the treatment. Ozone treatment significantly increases GSH levels compared to the control group, but not other REDOX markers. The treatments were safe and welltolerated. Also, a pilot, open-label, phase IV clinical trial study was performed in 40 SARS-CoV-2 convalescent patients (with symptoms extending beyond three weeks since negative PCR test) distributed at random into 2 groups. One group was treated with BIOPLA (dietary complement based on a concentrated protein - mineral elaborated from human placental after born, 1 capsule of 400 mg during 30 days) and the ozone group treated with rectal ozone application (ozone concentration between 20 and 35 mg/L and volume between 150 and 200 ml, 20 sessions, one per day) + BIOPLA. Both groups were treated and followed for one month. Twenty individuals supposedly healthy were enrolled and evaluated as the control group. Effect evaluation showed beneficial improvement in both treated groups resulting in 85% of patients for BIOPLA plus RIO3T and 37% for BIOPLA (p